Bloomberg Law
July 18, 2022, 9:17 PMUpdated: July 19, 2022, 3:20 PM

Jazz Again Sues Avadel on Xyrem Rival and ‘Misguided Agenda’ (1)

Christopher Yasiejko

Jazz Pharmaceuticals Inc. filed a lawsuit alleging that a narcolepsy drug proposed by Avadel CNS Pharmaceuticals LLC infringes a patent related to Jazz’s Xyrem that Avadel, in a related case, has asked a Delaware federal judge to remove from Xyrem’s entry in the FDA’s registry of approved drugs.

Jazz says it received written notice on June 7 of the allegation that the patent’s claims are invalid, unenforceable, or wouldn’t be infringed by the branded rival, proposed by a unit of Avadel Pharmaceuticals PLC, according to a complaint filed July 15 in the US District Court for the District of ...